Pediatric AIDS prognosis using somatic growth velocity

AIDS

Volumn 12, Issue 11, 1998, Pages 1361-1369

  Carey, Vincent J ^a   Yong, Florence H ^b   Frenkel, Lisa M ^c   McKinney Jr , Ross E ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Auxology; Growth and development; Growth curves; Pediatric AIDS

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD GROWTH; CLINICAL TRIAL; FEMALE; GROWTH RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STATISTICAL ANALYSIS;

EID: 0032581591     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00019     Document Type: Article

References (29)

1. McKinney Jr RE, Robertson JWR, Duke Pediatric AIDS Clinical Trials Unit: Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr 1993, 123:579-582.
2. Miller TL, Evan SJ, Orav EJ, Morris V, McIntosh K, Winter HS: Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr 1993, 57:588-592.
3. Saavedra JM, Henderson RA, Perman JA, Hutton N, Livingston RA, Yolken RH: Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch Pediatr Adolesc Med 1995, 149:497-502.
4. McKinney Jr RE, Wilfert C: Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr 1994, 125:728-733.
5. Moye J, Rich KC, Kalish LA, Sheon AR, Diaz C, Cooper ER: Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr 1996, 128:58-69.
6. Roche AF, Himes JH: Incremental growth charts. Am J Clin Nutr 1980, 33:2041-2052.
7. Baumgartner RN, Roche AF, Himes JH: Incremental growth tables: supplementary to previously published charts. Am J Clin Nutr 1986, 43:711-722.
8. Englund JA, Baker CJ, Raskino C, et al.: Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group Study 152 Team. N Engl J Med 1997, 336:1704-1712.
9. Bakshi SS, Britto P, Capparelli E, et al.: Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997, 175:1039-1050.
10. Kline MW, Van Dyke RB, Lindsey JC, et al.: A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics 1998, 101:214-220.
11. Brettler DB, Forsberg A, Bolivar E, Brewster F, Sullivan J: Growth failure as a prognostic indicator for progression to acquired immunodeficiency symdrome in children with hemophilia. J Pediatr 1990, 117:584-588.
12. Clarick RH, Hanekom WA, Yogev R, Chadwirk EC: Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997, 99:354-357.
13. Hamill PVV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM: Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979, 32:607-629.
14. Dibley MJ, Goldsby JB, Staehling NW, Trowbridge FL: Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr 1987, 46:736-748.
15. Dibley MJ, Staehling N, Nieburg P, Troivbridge FL: Interpretation of z-score anthropometric indicators derived from the international growth reference. Am J Clin Nutr 1987, 46:749-762.
16. Hastie T, Loader C: Local regression: automatic Kernel carpentry. Stat Sci 1993, 8:120-129.
17. Cole TJ, Green PJ: Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 1992, 11:1305-1319.
18. Picard RR, Berk KN: Data splitting. Am Stat 1990, 44:140-147.
19. Picard RR, Cook RD: Cross-validation of regression models. J Am Stat Assoc 1984, 79:575-583.
20. Shapiro SS, Wilk MB: An analysis-of-variance test for normality (complete samples). Biometrika 1965, 52:591-611.
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 1958, 53:457-481.
22. Cox DR: Regression models and life tables. J R Stat Soc Series B 1972, 34:187-220.
23. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York: John Wiley; 1980.
24. Cameron N: Conditional standards for growth in height of British children from 5.0 to 15.99 years of age. Ann Hum Biol 1980, 7:331-337.
25. Cole TJ: Growth charts for both cross-sectional and longitudinal data. Stat Med 1994, 13:2477-2492.
26. Mellor J, Rinaldo CJ, Gupta P, White R, Todd J, Kingsley L: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
27. Shearer W, Quinn T, LaRussa P, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997, 336:1337-1342.
28. Mofenson LM, Korelitz J, Meyer III WA, et al.: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997,175:1029-1038.
29. Ogino MT, Dankner WM, Spector SA: Development and significance of zidovudine resistance in children infected with HIV. J Pediatr 1993, 123:1-8.